Giredestrant

吉雷司群

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameGiredestrant
Drug Alias Name酒石酸吉雷司群GDC-9545RG-6171
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptors degraders
TargetsEstrogen receptors
Therapy Area/IndicationsMetastatic breast cancerEndometrial NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[65] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesFondazione Oncotech IncRoche Pharma (Schweiz) AgF. Hoffmann-La Roche Ag +[7] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerEndometrial NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A